1. Search Result
Search Result
Results for "

Cx

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

6

Peptides

3

Inhibitory Antibodies

1

Natural
Products

24

Recombinant Proteins

1

Isotope-Labeled Compounds

2

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139897

    iGluR Neurological Disease
    CX 717 is a positive allosteric modulator of AMPA receptor. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD) .
    <em>CX</em> 717
  • HY-12505
    CX546
    2 Publications Verification

    iGluR Autophagy Neurological Disease
    CX546 is a first-generation and selective benzamide-type positive AMPAR modulator. CX546 is a prototypical ampakine agent and has antipsychotic effects .
    <em>CX</em>546
  • HY-50733A

    Casein Kinase Ras Apoptosis Cancer
    CX-5011 is a CK2 inhibitor. CX-5011 also induces Rac1 activation. CX-5011 induces apoptosis and induces cancer cell death .
    <em>CX</em>-5011
  • HY-100178

    Monoamine Oxidase Neurological Disease
    CX-157 is a reversible inhibitor of monoamine oxidase-A (MAO-A) with an EC50 of 19.3 ng/mL.
    <em>CX</em>-157
  • HY-117830

    Phosphatase Endocrinology
    CX08005 is a competitive PTP1B inhibitor. CX08005 can directly enhance the action of insulin in vivo and in vitro and improve insulin resistance .
    <em>CX</em>08005
  • HY-P99799

    Cx-072

    PD-1/PD-L1 Cancer
    Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity .
    Pacmilimab
  • HY-18095

    Pim Cancer
    CX-6258 is a potent and kinase selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .
    <em>CX</em>-6258
  • HY-18095A

    Pim Cancer
    CX-6258 hydrochloride hydrate is a potent and kinase selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .
    <em>CX</em>-6258 hydrochloride hydrate
  • HY-18095B

    Pim Cancer
    CX-6258 hydrochloride is a potent and kinase selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .
    <em>CX</em>-6258 hydrochloride
  • HY-10937

    Cx-691; Org24448

    iGluR Neurological Disease
    Farampator (CX-691;Org24448) is an AMPA receptor positive modulator.
    Farampator
  • HY-50855
    Silmitasertib
    Maximum Cited Publications
    31 Publications Verification

    Cx-4945

    Casein Kinase Autophagy Cancer
    Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
    Silmitasertib
  • HY-13323
    CX-5461
    25+ Cited Publications

    DNA/RNA Synthesis Cancer
    CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively .
    <em>CX</em>-5461
  • HY-110175

    iGluR Neurological Disease
    CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression .
    <em>CX</em>614
  • HY-13323A
    CX-5461 dihydrochloride
    25+ Cited Publications

    DNA/RNA Synthesis Cancer
    CX-5461 dihydrochloride is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis, with IC50s of 142 nM in HCT-116, 113 nM in A375, and 54 nM in MIA PaCa-2 cells, and shows little or no effect on Pol II (IC50 ≥25 μM).
    <em>CX</em>-5461 dihydrochloride
  • HY-10522
    LEDGIN6
    4 Publications Verification

    Cx05168; Cx04328

    HIV HIV Integrase Infection
    LEDGIN6 (CX05168) is a quinoline-based protein-protein interaction inhibitor of LEDGF/p75 and HIV integrase .
    LEDGIN6
  • HY-14776
    Quarfloxin
    4 Publications Verification

    Cx-3543

    DNA/RNA Synthesis Cancer
    Quarfloxin (CX-3543), a fluoroquinolone derivative with antineoplastic activity, targets and inhibits RNA pol I activity, with IC50 values in the nanomolar range in neuroblastoma cells. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template .
    Quarfloxin
  • HY-10933S

    BDP 12-d10

    Isotope-Labeled Compounds iGluR Neurological Disease
    CX516-d10 is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI)[1].
    <em>CX</em>516-d10
  • HY-RS03378

    Small Interfering RNA (siRNA) Others

    CX3CL1 Human Pre-designed siRNA Set A contains three designed siRNAs for CX3CL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CX3CL1 Human Pre-designed siRNA Set A
    CX3CL1 Human Pre-designed siRNA Set A
  • HY-RS03379

    Small Interfering RNA (siRNA) Others

    CX3CR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CX3CR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CX3CR1 Human Pre-designed siRNA Set A
    CX3CR1 Human Pre-designed siRNA Set A
  • HY-RS03380

    Small Interfering RNA (siRNA) Others

    Cx3cr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cx3cr1 Mouse Pre-designed siRNA Set A
    Cx3cr1 Mouse Pre-designed siRNA Set A
  • HY-RS03381

    Small Interfering RNA (siRNA) Others

    Cx3cr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cx3cr1 Rat Pre-designed siRNA Set A
    Cx3cr1 Rat Pre-designed siRNA Set A
  • HY-10933
    CX516
    1 Publications Verification

    BDP 12

    iGluR Neurological Disease
    CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .
    <em>CX</em>516
  • HY-119378

    Cx 295

    Proteasome Apoptosis Neurological Disease
    AK 295 (CX 295) is a calpain inhibitor that inhibits apoptosis through a calpain-dependent pathway. AK 295 improves neurological function in a rat model of spinal cord injury (SCI). AK 295 can be used in the study of neurodegenerative diseases, such as bulbar amyotrophy, stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis .
    AK 295
  • HY-50855B
    Silmitasertib sodium salt
    Maximum Cited Publications
    31 Publications Verification

    Cx-4945 sodium salt

    Casein Kinase Autophagy Cancer
    Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
    Silmitasertib sodium salt
  • HY-109046
    Tulrampator
    1 Publications Verification

    Cx-1632; S-47445

    iGluR mTOR Neurological Disease
    Tulrampator (S-47445) is an orally active selective AMPA receptor modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder .
    Tulrampator
  • HY-116685

    Others Neurological Disease
    AF-CX 1325 has strongest antiepileptic effect .
    AF-<em>CX</em> 1325
  • HY-N12110

    Toll-like Receptor (TLR) SARS-CoV Infection
    SMU-CX1 is a specific TLR3 inhibitor (IC50: 0.11 μM) with IC50 ranging from 0.14-0.33 μM against multiple influenza A virus subtypes. SMU-CX1 inhibits the viral PB2 and NP proteins with an IC50 of 0.43 μM for SARS-CoV-2 activity. SMU-CX1 also inhibits inflammatory factors in host cells, including IFN-β, IP-10, and CCL-5 .
    SMU-<em>CX</em>1
  • HY-P1136B

    Gap Junction Protein Cardiovascular Disease Inflammation/Immunology
    TAT-Gap19, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice .
    TAT-Gap19
  • HY-P1136C

    Gap Junction Protein Cardiovascular Disease Inflammation/Immunology
    TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice .
    TAT-Gap19 TFA
  • HY-P1136

    Gap Junction Protein Cardiovascular Disease
    Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial .
    Gap19
  • HY-P1136A
    Gap19 TFA
    3 Publications Verification

    Gap Junction Protein Cardiovascular Disease
    Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial .
    Gap19 TFA
  • HY-P99404

    CXCR Inflammation/Immunology Cancer
    Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion .
    Quetmolimab
  • HY-149318

    Others Others
    VRT-534 targets connexin 26 (Cx26). Vrt-534 exhibits dose-responsive binding to recombinant WT Cx26 and mutant Cx26 K188N with EC50 value of 19 μM and 5 μM, respectively. Vrt-534 can be used in research related to hearing impairment .
    VRT-534
  • HY-106225

    ZP123

    Gap Junction Protein Cardiovascular Disease
    Rotigaptide (ZP123) is a novel and specific modulator of connexin 43 (Cx43). Rotigaptide prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress. Rotigaptide is a potent antiarrhythmic peptide (AAP) with improved stability and has the potential for the investigation of cardiac arrhythmias-specifically atrial fibrillation .
    Rotigaptide
  • HY-13848
    AZD8797
    10+ Cited Publications

    KAND567

    CX3CR1 CXCR Inflammation/Immunology Endocrinology
    AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively .
    AZD8797
  • HY-107456
    E6130
    2 Publications Verification

    CX3CR1 Inflammation/Immunology Endocrinology
    E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.
    E6130
  • HY-123918
    JMS-17-2
    5+ Cited Publications

    CX3CR1 Endocrinology Cancer
    JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells .
    JMS-17-2
  • HY-123918A

    CX3CR1 Endocrinology Cancer
    JMS-17-2 hydrochloride is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 hydrochloride impairs metastatic seeding and colonization of breast cancer cells .
    JMS-17-2 hydrochloride
  • HY-15724
    Vercirnon
    1 Publications Verification

    GSK-1605786; CCx282-B; Traficet-EN

    CCR Inflammation/Immunology Endocrinology
    Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 µM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .
    Vercirnon
  • HY-15724A
    Vercirnon sodium
    1 Publications Verification

    GSK-1605786 sodium; CCx282-B sodium; Traficet-EN sodium

    CCR Inflammation/Immunology Endocrinology
    Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 µM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .
    Vercirnon sodium
  • HY-100516

    UR-8880

    COX Inflammation/Immunology
    Cimicoxib (CX) is an orally active potent and selective COX-2 (cyclo-oxygenase-2) inhibitor. Cimicoxib exhibits promising anti-inflammatory and analgesic activity. The PK parameters of Cimicoxib in dogs given precise (2 mg/kg) and approximate doses (1.95-2.5 mg/kg) are similar .
    Cimicoxib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: